Immortal Dragons aims to ‘redefine how capital fuels scientific breakthroughs in longevity and healthspan.’
Longevity focused investment fund Immortal Dragons has launched with $40 million in assets under management and a mission to catalyze breakthroughs in life extension and healthspan through strategic investment and advocacy. Based in Singapore, and already with a portfolio of more than 15 companies, the fund is committed to supporting technologies that confront aging and death as solvable scientific challenges, rather than immutable biological facts.
Immortal Dragons’ investment strategy spans multiple areas, backing projects in xenotransplantation, cryopreservation and regenerative medicine aimed at replacing or repairing aging biological systems. Investments also include gene therapies that target root causes of aging, 3D bioprinting to produce therapeutic tissues and organs, and the development of foundational infrastructure for the longevity sector. Its infrastructure work encompasses accelerated clinical trial platforms, regulatory sandboxes, and other systemic enablers crucial for scaling innovation in the field – including an investment in Longevity.Technology.
Operating under a single-LP structure, Immortal Dragons uses its own capital to invest swiftly in underfunded areas that traditional venture capital often neglects. The fund prioritizes impact over economic returns – an approach that enables support for both “moonshot” scientific efforts and the creation of ecosystems that sustain long-term progress.
Immortal Dragons is guided by the personal conviction and leadership of its founder, Boyang Wang, a tech entrepreneur with a lifelong interest in existence, survival and consciousness.
“The challenges of aging and disease are engineering problems that humanity can and shall overcome,” he told us in a recent interview.
Beyond its financial investments, Immortal Dragons is also deeply involved in global longevity advocacy. It translates and publishes longevity-related books, disseminates expert talks through Chinese-language platforms, sponsors international conferences and supports initiatives such as Vitalist Bay and the Aging Research and Drug Discovery (ARDD) conference. Through these efforts, the fund aims to build public awareness and community engagement while fostering cross-cultural and international collaboration.
“These are young, brave and energetic people committed to resolving the main challenge humanity faces: aging,” said Professor Peter Lidsky of the City University of Hong Kong’s Biomedical Science department. “Their foundation helped me a lot in translating one of my lectures to Chinese, and I hope our collaboration will prosper in the future.”
With strong connections across Eastern and Western markets, Immortal Dragons positions itself as a bridge linking capital, research and institutional development. By integrating investment with advocacy, and by championing a bold rethinking of human aging, the fund seeks to accelerate the arrival of a future where radical life extension is not only possible, but accessible.
“I have been frustrated for many years that there has been too little longevist activity in China, and I am delighted that that is now changing, with the work of a group that is bringing my and others’ work to the Chinese public,” said Aubrey de Grey, president of the LEV Foundation.
